Buprenorphine transdermal - Grunenthal
Alternative Names: Transdermal buprenorphine - Grunenthal; Transtec; Transtec twice-weeklyLatest Information Update: 13 Jan 2022
At a glance
- Originator Grunenthal
- Developer Grunenthal; Napp Pharmaceutical Group; Norpharma; Taiwan Mundipharma Pharmaceuticals
- Class Cyclopropanes; Drug withdrawal therapies; Morphinans; Opioid analgesics; Small molecules
- Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor agonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Cancer pain; Pain
Most Recent Events
- 01 Jun 2017 Launched for Cancer pain in Taiwan (Transdermal) (NCT04315831)
- 01 Apr 2014 Buprenorphine licensed to Taiwan Mundipharma in Asia, Middle East and Africa
- 31 May 2007 Launched for Pain in Hungary (Transdermal)